Preclinical CRO PharmOptima joins GBG research consortium

By Melissa Fassbender contact

- Last updated on GMT

Preclinical CRO PharmOptima joins GBG research consortium

Related tags: Mergers and acquisitions, Contract research organization

Genesis Biotechnology Group (GBG) has acquired the preclinical CRO PharmOptima in order to provide customers with a single point-of-contact throughout their drug development programs.

Genesis Biotechnology Group (GBG) is a consortium of an integrated group of biotechnology and research companies. Its acquisition of the preclinical Contract Research Organization (CRO) PharmOptima, adds to its existing drug development segment, which includes Invivotek and Venenum Biodesign.

Ben Bandaru, Ph.D., Director of Mergers & Acquisitions at GBG, told us it has a history of making acquisitions that add to its capabilities and expand its services.

Ultimately, this addition gives our clients the ability to work with one provider for early discovery through pre-clinical candidate identification without sacrificing time or talent​,” he said.

PharmOptima services integrate into our current workflow to complete the discovery pathway providing assay and reagent development capabilities, ADME/PK and bioanalysis services that ultimately contribute to selection of a de-risked pre-clinical candidate​.”

Additionally, PharmOptima brings expertise in the growing ophthalmology therapeutics field, which Buiakova said further enhances GBG’s services portfolio “to meet the growing market demand​.”

(Feature image: iStock/ALotOfPeople)

Related news

Show more

Related products

show more

Has EDC Kept Up With Changes In Clinical Trials?

Has EDC Kept Up With Changes In Clinical Trials?

Oracle Health Sciences | 14-Dec-2020 | Technical / White Paper

In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

CAR-T Cell Therapy

CAR-T Cell Therapy

Q² Solutions | 01-Sep-2020 | Clinical Study

Cell therapy involves the transfer of genetically altered cells into a patient. As a global central laboratory services organization, we provide testing...

Related suppliers

Follow us

Products

View more

Webinars